OCGN
NASDAQ · Biotechnology
Ocugen Inc
$2.10
+0.06 (+2.94%)
Open$2.22
Previous Close$2.04
Day High$2.29
Day Low$1.97
52W High$1.96
52W Low$0.52
Volume—
Avg Volume3.05M
Market Cap521.34M
P/E Ratio—
EPS$-0.22
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,327.1% upside
Current
$2.10
$2.10
Target
$29.97
$29.97
$22.68
$29.97 avg
$39.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.92M | 214.85M | 205.76M |
| Net Income | -65,413,728 | -16,849,465 | -19,542,916 |
| Profit Margin | -1,333.0% | -7.8% | -9.5% |
| EBITDA | -63,020,143 | -26,350,714 | -23,624,019 |
| Free Cash Flow | — | -15,177,197 | -13,829,123 |
| Rev Growth | +366.3% | +3.8% | +8.3% |
| Debt/Equity | 0.97 | 0.42 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |